Weight Loss Blockbuster Wegovy Wins Expanded Approval for Heart Benefits [Jx4g5neqfbJ]

Weight Loss Blockbuster Wegovy Wins Expanded Approval for Heart Benefits [Jx4g5neqfbJ]

| 1h 28m 28s | Video has closed captioning.

For more on this story: Novo Nordisk’s blockbuster obesity drug Wegovy has scored FDA approval for reducing the risk of heart conditions like heart attack and stroke. In a cardiovascular outcomes trial, Wegovy was shown to cut the risk of major adverse cardiovascular events by 20 percent compared to placebo. Sales of the blockbuster drug totalled $4.6 billion in 2023. #Wegovy #WeightLossDrug #ObesityDrug #NovoNordisk #Semaglutide #GLP1Agonist #HeartHealth #CardiovascularDisease #FDA #FDAApproval #WeightLoss #Obesity #opra weight loss gummy #keto acv gummies diet plan #keto bhb gummies review